WO2005007839A1 - ノッチリガンドDelta-1、GM-CSF、TGF-βを用いたヒト末梢血単核球であるCD14陽性細胞からのランゲルハンス細胞の調製方法 - Google Patents
ノッチリガンドDelta-1、GM-CSF、TGF-βを用いたヒト末梢血単核球であるCD14陽性細胞からのランゲルハンス細胞の調製方法 Download PDFInfo
- Publication number
- WO2005007839A1 WO2005007839A1 PCT/JP2004/010783 JP2004010783W WO2005007839A1 WO 2005007839 A1 WO2005007839 A1 WO 2005007839A1 JP 2004010783 W JP2004010783 W JP 2004010783W WO 2005007839 A1 WO2005007839 A1 WO 2005007839A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- langerhans
- cell
- delta
- preparing
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 226
- 210000001821 langerhans cell Anatomy 0.000 title claims abstract description 107
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 80
- 239000003446 ligand Substances 0.000 title claims abstract description 67
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 title claims abstract description 30
- 108700041286 delta Proteins 0.000 title claims description 71
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract description 80
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title abstract description 9
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title abstract description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract description 9
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims abstract description 74
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims abstract description 73
- 238000012258 culturing Methods 0.000 claims abstract description 24
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 claims description 35
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 108010029697 CD40 Ligand Proteins 0.000 claims description 18
- 102100032937 CD40 ligand Human genes 0.000 claims description 18
- 102000000905 Cadherin Human genes 0.000 claims description 18
- 108050007957 Cadherin Proteins 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 18
- 208000035473 Communicable disease Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 14
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 13
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 13
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 13
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 13
- 208000026935 allergic disease Diseases 0.000 claims description 13
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 12
- 206010052779 Transplant rejections Diseases 0.000 claims description 12
- 208000024908 graft versus host disease Diseases 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 238000002054 transplantation Methods 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 108700003486 Jagged-1 Proteins 0.000 claims description 5
- 102100032702 Protein jagged-1 Human genes 0.000 claims description 5
- 108700037966 Protein jagged-1 Proteins 0.000 claims description 5
- 102100032733 Protein jagged-2 Human genes 0.000 claims description 5
- 101710170213 Protein jagged-2 Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 102000043129 MHC class I family Human genes 0.000 claims description 2
- 108091054437 MHC class I family Proteins 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 102000014736 Notch Human genes 0.000 description 62
- 108010070047 Notch Receptors Proteins 0.000 description 62
- 230000014509 gene expression Effects 0.000 description 37
- 210000004443 dendritic cell Anatomy 0.000 description 34
- 239000011886 peripheral blood Substances 0.000 description 23
- 210000005259 peripheral blood Anatomy 0.000 description 23
- 210000001616 monocyte Anatomy 0.000 description 21
- 108090000978 Interleukin-4 Proteins 0.000 description 18
- 102000004388 Interleukin-4 Human genes 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 229940028885 interleukin-4 Drugs 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 102000003812 Interleukin-15 Human genes 0.000 description 10
- 108090000172 Interleukin-15 Proteins 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102100030798 Transcription factor HES-1 Human genes 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 102100035793 CD83 antigen Human genes 0.000 description 5
- -1 CD86 Proteins 0.000 description 5
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 5
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 5
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
- 108010010995 MART-1 Antigen Proteins 0.000 description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108010051152 Carboxylesterase Proteins 0.000 description 3
- 102000013392 Carboxylesterase Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101710150912 Myc protein Proteins 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101800001707 Spacer peptide Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- UDLNDXDUOBMZIQ-GFCCVEGCSA-N 3-[(1R)-1-[[3-chloro-7-fluoro-6-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-2-methyl-1,5-naphthyridin-4-yl]amino]ethyl]-4-fluorobenzonitrile Chemical compound ClC=1C(=NC2=CC(=C(N=C2C=1N[C@H](C)C=1C=C(C#N)C=CC=1F)C=1C=NC(=NC=1)C(C)(C)O)F)C UDLNDXDUOBMZIQ-GFCCVEGCSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000002549 cytobiological effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108700027921 interferon tau Proteins 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
Definitions
- the present invention relates to the culture of epidermal Langerians cells (LC), which is a subtype of dendritic cells (DCs), and comprises converting Notch ligands (Notch ligands) from positive cells that are human peripheral blood mononuclear cells.
- LC epidermal Langerians cells
- DCs dendritic cells
- Notch ligands Notch ligands
- the cells can be used as therapeutic agents for cancer, infectious disease, graft rejection, graft-versus-host disease, autoimmune disease or allergic disease.
- DCs Dendritic cells
- LC Epidermal Langerhans cells
- E-Cadherin cadherin
- CCR6 Chidermal Langerhans cells
- LC triggers an appropriate immune response to various foreign substances that have entered the skin. Specifically, LC captures foreign substances such as pathogens and tumor cells that have invaded the skin, then migrates to regional lymph nodes, where it processes the processed antigens into naive T cells or memory T cells. To activate or re-activate them and effectively induce a specific immune response to antigens derived from the foreign body.
- Activated T cells infiltrate foreign tissue-invaded tissues, promote their removal, and protect tissues from excessive tissue damage.
- Human LC was obtained from allogeneic bone marrow transplantation for aplastic anemia, since the LC in the skin of the transplanted patient expressed the same histocompatibility antigen as the bone marrow donor (donor). It was thought to be cell-derived (Volc-Platzer B et al., N Engl J Med 310: 1123-1124, 1984).
- CD34-positive hematopoietic progenitor cells from umbilical cord blood or peripheral blood were converted to granulocyte-macrophage colony-stimulating factor (GM-CSF) + tumor necrosis fact or-a (TNF- ⁇ ;) It has been reported that when cultured in culture, some of the cultured cells have differentiated into LC (Caux C et al., Ature 360: 258-261, 1992; Caux C et al., J Exp Med 184: 695-706, 1996; Strunk D et al., Blood 87: 1292-1302, 1996), indicating that LC was derived from hematopoietic stem cells.
- LC granulocyte-macrophage colony-stimulating factor
- hematopoiesis such as GM-CSF + interleukin4 (IL-4) + transforming growth factor-j3 (TGF- / 3), GM-CSF + IL-15, GM-CSF + TGF- / 3, etc.
- Notch ligand Delta-1 (Ohishi K et al., Int J Hematol 75: 449-459, 2002; Ohishi K et al., Semin Cell Dev Biol 14: 143-150, 2003), CD34 derived from human peripheral blood monocytes or bone marrow It has also been reported to be involved in the differentiation of dermal DC from positive cells (Ohishi K et al., Blood 98: 1402-1407, 4010783
- CD14-positive cells which are human peripheral blood mononuclear cells.
- the present inventors have eagerly studied a method for culturing and differentiating dendritic cells having antigen-presenting ability in order to utilize Langerhans, a subtype of dendritic cells, for cell biology research and the development of vaccine cell therapy using DC. Study was carried out. Conventionally, attempts have been made to obtain Langerhans cells by culturing. However, cells that can be said to be Langerhans cells have not been obtained in view of the expressed antigen of the cells.
- the present inventors cultured CD14-positive cells, which are human peripheral blood mononuclear cells, in an animal cell culture medium using Notch ligand Delta-1, GM-CSF, and TGF-j3. They have found that Langerhans cells can be obtained, and have completed the method for preparing Langerhans cells of the present invention.
- the present invention is as follows.
- a method for transmitting Langerhans cells comprising transmitting Notch signals to Notch of human peripheral blood mononuclear cells using Notch ligand, and culturing the mononuclear cells in the presence of GM-CSF and TGF- Preparation method,
- the Notch ligand constitutes a fusion peptide with another peptide, an antibody against the other peptide is immobilized in a culture vessel, and the Notch ligand is cultured through the binding of the antibody and the other peptide.
- the notch ligand is selected from the group consisting of Delta-1, Delta-2, Delta-3, Delta-4, Jagged-1 and Jagged-2, and is any one of [1] to [5].
- a method for preparing Langerhans cells for treating cancer or infectious disease comprising culturing peripheral blood mononuclear cells collected from a human in the presence of Notch ligand, GM-CSF and TGF- ⁇ ,
- Cancer infectious disease, transplant rejection associated with cell, organ or tissue transplant, including culturing peripheral blood mononuclear cells from humans in the presence of Notch ligand, GM-CSF and TGF-j3
- FIG. 1 shows the results of analysis of the traits of cells induced from CD14-positive cells by GM-CSF + IL-4 + TGF-j3 in the presence or absence of Delta-1.
- FIG. 2 shows the results of analysis of the traits of cells induced from CD14-positive cells by GM-CSF + IL-15 in the presence or absence of Delta-1.
- FIG. 3 is a view showing the results of analysis of the traits of cells induced from CD14-positive cells by GM-CSF + TGF-j3 in the presence or absence of Delta-1.
- Figure 4 shows the expression of E-force doherin and Langerin in 01 & positive cells in Delta-1 + GM-CSF + 161 ? -Like cells and the expression of E-force dherin and CCR6 in Langerin-positive cells. It is a figure showing a result of analysis.
- FIG. 5 is a diagram showing the results of analysis of expression of antigen-presenting function-related molecules in cells induced by Delta-1 + GM-CSF + TGF- / 3.
- FIG. 6 is a diagram showing the enhanced expression of the HES-1 gene by Delta-1 in CD14-positive cells.
- FIG. 7 is a photograph showing an electron microscope image of the cultured cells.
- FIG. 8 is a diagram showing the results of an examination of the uptake of FITC-dextran by LC.
- FIG. 9 is a diagram showing the expression of HLA-ABC, HLA-DR, CD80, CD86, CD40, CD54, and CD83 in LC matured by CD40 ligand and TNF-.
- FIG. 10 is a view showing activation of peptide-specific CD8-positive cells of mature LC generated from CD14-positive cells.
- Figure 11 shows the results of stimulation of autologous CD4-positive cells with mature: LC and mature DC. '' Best mode for carrying out the invention
- the present invention is a method for preparing Langerhans cells, comprising culturing human peripheral blood mononuclear cells in the presence of Notch ligand, GM-CSF and TGF- / 3.
- Human peripheral blood mononuclear cells can be obtained by known methods from blood collected from humans.
- peripheral blood can be collected from a human and obtained by specific gravity centrifugation using FicoU-HypaQue or the like.
- CD14-positive cells among human peripheral blood mononuclear cells are used.
- the CD14-positive cells can be isolated by a known method, for example, by using MACS Microbead (Mitenyi Biotec).
- the purity of CD14-positive cells used for the preparation of Langerhans cells is 90% or more, preferably 95% or more, and more preferably. 98% or more. Whether or not the cells used are monocytes can be determined by, for example, performing non-specific esterase staining.
- CD14-positive cells thus obtained from human peripheral blood mononuclear cells are treated with Notch ligand, GM-CSF and TGF- / 3.
- the treatment refers to bringing CD14-positive cells into contact with these compounds, and these compounds may be added and cultured at the time of culturing CD14-positive cells.
- all of Notch ligand, GM-CSF and TGF- ⁇ may be added in a dissolved state to the culture medium for CD-positive cells, but the Notch ligand is added to the inner surface of the vessel used for culture as described later. It is desirable to be immobilized and brought into contact with cells.
- Notch is a protein that is involved in signal transduction related to cell differentiation and possessed by cells. Notch is activated by binding of Notch ligand to Notch.
- Notch ligands include Delta (De lta) and Jagged (Delta-K Delta-2, De11a-3 and ZSJ) 11a-4 and Jagged-1 and Jagged-2, respectively. There is a homologue called Mumm JS et al., Dev. Biol., 228, 151-165, 2000.
- any of these Notch ligands can be used, and also include Notch ligands to be discovered in the future.
- Delta-1 is particularly preferred.
- Notch ligand or DNA encoding Notch ligand can be isolated from human cells expressing De Ua-1 such as keratinocytes by a gene amplification method. It can also be synthesized based on information (Gray GE et al., Am. J. Pathol., 154, 785-793, 1999).
- GM-CSF and TGF- / 3 can be either naturally occurring recombinant ones or can be easily prepared from known gene sequence information, or commercially available ones.
- a medium usually used for culturing animal cells may be used, and examples thereof include RPMI 1640, DMEM, and MEM. If necessary, add animal serum such as FCS, sugars, amino acids, antibiotics, etc. to the medium.
- animal serum such as FCS
- a serum-free medium or a human-derived serum or a plasma or a culture medium using its components instead of animal serum such as FCS is preferable.
- the culture vessel a vessel usually used for cell culture may be used. 04 010783 A tissue, a flask, or the like may be used.
- the culture vessel is made by bonding suitable functional groups such as polyamino acid and amino groups suitable for immobilization of proteins and the like.
- suitable functional groups such as polyamino acid and amino groups suitable for immobilization of proteins and the like.
- a container is used. Alternatively, it may be performed using a blood collection bag.
- the culture format is not limited, and may be any of batch culture and continuous culture.
- the density of CD14-positive cells obtained from human peripheral blood during culture is 1 ⁇ 10 4 to 1 ⁇ 1 7 AiL, preferably 1 ⁇ 10 5 to 1 / mL.
- the GM-CSF concentration is preferably 10-100 ng / mL
- TGF-] 3 is preferably 1-100 ng / mL.
- the Notchi ligand is preferably used by immobilizing it on the inner surface of a culture vessel or the like.
- the solid phase may be immobilized not only on the inner surface of the culture vessel but also on particles such as polystyrene beads, and the immobilized particles may be added to the culture system during cell culture.
- the notch ligand may be immobilized directly on the inner surface of the container or the like, but is preferably immobilized via a spacer or the like.
- the spacer is not limited, but it is desirable to use a peptide consisting of several to several tens of amino acids. Examples of peptides used for the spacer include myc protein, V5 protein, and polyhistidine such as 6XHis. These spacers and Notch ligand are bound, but the binding method is not limited, and DNA encoding these peptides and DAN encoding the Notch ligand are fused in-frame to form appropriate host cells. It may be introduced and expressed as a recombinant fusion protein.
- the DNA fusion method and the production of the recombinant protein can be carried out by known methods.
- J. Sambrook, EF Friends & L Mani is (1989): Molecular Cloning, alboratory manual, second edition , Cold Spring Harbor Laboratory Press and Ed Harlow and David Lane (1988): can be performed according to methods well-known to those skilled in the art, such as Antibodies, alboratory manual, and Cold Spring Harbor Laboratory Press. Good.
- Notch ligands even if other peptides are bound instead of Notch ligand alone, cells are treated with Notch ligands as long as the Notch ligand transmits Notch signals to the cells when the cells are cultured. That.
- the peptide bound to one molecule of Notch ligand is not limited to one molecule. As the number of peptide molecules increases, the density of Notch ligand immobilized increases, and the action of Notch ligand is enhanced. One to several tens, preferably one to fifteen, peptides are linked.
- a specific antibody that binds to the spacer peptide is bound to the inner surface of the culture vessel in advance, and the notch ligand is indirectly bound to the inner surface of the culture vessel by binding the spacer peptide to the antibody. And so on.
- the antibody may be bonded to the inner surface of the culture vessel or the like by physical adsorption, or may be chemically bonded using a specific functional group, and can be performed by a known method.
- the higher the solid phase density the better.
- a concentration of 1 ⁇ / 11 ⁇ to 20 ⁇ / 1 ⁇ is used in the culture vessel.
- Anti-1 ⁇ (; antibody should be immobilized.
- Culture of CD14-positive cells obtained from human peripheral blood in the presence of Notch ligand, GM-CSF and TGF- / 3 can be carried out for about 1 to 10 days, for example, 6 days, during which time a part of the culture medium may be used. Or replace all. At this time, by examining the expression of the surface antigen of the cultured cells by FACS or the like, the culture period in which Langerhans cells can be obtained can be appropriately determined.
- Langerhans cells can be prepared by isolating CD14-positive cells from peripheral blood mononuclear cells obtained from human peripheral blood and culturing them in the presence of notch ligand, GM-CSF and TGF-j3.
- the Notch ligand binds to the notch originally possessed by the cell, and transmits the Notch signal to the cell. That is, treating a cell with a Notch ligand means transmitting Notch signals to the notch of the cell using the Notch ligand.
- E-force doherin, Langerin and CCR6 are expressed on the cell surface.
- HLA-AB an MHC class I molecule
- HLA-DR an MHC class I molecule
- CD80 and CD86 which are MHC class I molecules
- Whether or not these antigens are expressed must be determined by microscopic observation, etc., to determine whether cells have been stained using antibodies against these antigens and labeled with a chromogenic enzyme, fluorescent compound, etc. Can be.
- the presence or absence of a surface antigen can be determined by immunostaining cells using these antibodies, and can also be determined using magnetic beads to which the antibodies are bound.
- the presence of a surface antigen can be determined using FACS or a flow cytometer.
- FACS and the flow cytometer for example, FACS Vant age (manufactured by Becton Dickinson), FAC S Cal ibur (manufactured by Becton's Dickinson) and the like can be used.
- GM-CSF and TGF-jS predominantly immature Langerhans cells can be obtained, and further matured to obtain mature Langerhans cells.
- IL-1 such as TNF-, LPS, IL-1 / 3, etc.
- Prostaglandins such as IL-6, PGE2, INF- ⁇ , ⁇ ,, CD40 ligand and the like, or combinations thereof, but are not limited thereto.
- Suitable concentrations as factors for maturing immature Langerhans cells include the range of 0.1 lng / mL to 100 g / niL.
- the TNF-concentration is preferably 1 to 200 ng / mL
- the CD40 ligand concentration is preferably 0.1 to 10_ig / mL
- the LPS concentration is preferably 0.1 to 10 ng / mL.
- the present invention also encompasses Langerhans cells obtained by culturing human peripheral blood mononuclear cells in the presence of Notch ligand, GM-CSF and TGF- ⁇ according to the method described above. Include.
- the Langerhans cells and the like express the surface antigen as described above.
- the present invention also includes a pharmaceutical composition containing the Langerhans cells obtained by the above method.
- the Langerhans cells of the present invention can be used for cell therapy, and a pharmaceutical composition containing the Langerhans cells of the present invention can be used as a pharmaceutical composition for use in cell therapy.
- the pharmaceutical composition is useful for the treatment of infectious diseases such as cancer and AIDS, the suppression of transplant rejection associated with cell, organ or tissue transplantation, the treatment of graft-versus-host disease, the treatment of autoimmune diseases or allergic diseases, Can be used for treatment.
- infectious diseases such as cancer and AIDS
- the suppression of transplant rejection associated with cell, organ or tissue transplantation the treatment of graft-versus-host disease
- the treatment of autoimmune diseases or allergic diseases Can be used for treatment.
- mature Langerhans cells are suitable for treatment of infectious diseases such as cancer and AIDS because they have an immunopotentiating effect
- immature Langerhans cells have an immunosuppressive effect
- It is suitable for suppressing transplant rejection associated with organ or tissue transplantation, treating graft-versus-host disease, and treating autoimmune diseases or allergic diseases.
- the Langerhans cells of the present invention may be used for the treatment of rheumatoid arthritis, multiple sclerosis, type I diabetes, uveitis, autoimmune myocarditis, myasthenia gravis, systemic lupus erythematosus.
- autoimmune hemolytic anemia systemic sclerosis, ulcerative colitis, Crohn's disease, Siedalen syndrome, autoimmune liver disease (eg, primary biliary cirrhosis), psoriasis, idiopathic thrombocytopenic purpura Disease, Goodpasture syndrome (eg, glomerulonephritis), pernicious anemia, Hashimoto's disease, vitiligo vulgaris, Behcet's disease, autoimmune gastritis, pemphigus, self-like illness like Guillain-Barre syndrome, HTLV-1 associated myelopathy It can also be used for the treatment of immune diseases or allergic diseases such as contact hypersensitivity, allergic rhinitis, food allergies and asthma.
- allergic diseases such as contact hypersensitivity, allergic rhinitis, food allergies and asthma.
- the Langerhans cells of the present invention When used for the treatment of cancer or infectious diseases, the Langerhans cells of the present invention can be used as they are after maturation, or CTLs (cytotoxic T lymphocytes) obtained by co-culturing peripheral blood of patients can be used. .
- CTLs cytotoxic T lymphocytes
- an antigen appropriately selected depending on the target disease is applied to the Langerhans cells of the present invention, and the application is performed for a period of several days. It may be given in vitro.
- the pharmaceutical composition containing the Langerhans cells of the present invention is used for treatment, 0.5 ⁇ 10 6 to 10 3 may be administered intravenously, subcutaneously, or intradermally.
- administration to patients can be performed at any time. Especially for transplant rejection and graft-versus-host disease associated with organ / tissue transplantation, administration prior to the expected treatment is preferable.
- the timing and dosage of Langerhans cells can be appropriately determined according to the type of disease, the severity of the disease, the condition of the patient, and the like.
- the present invention provides a method for cancer, infectious disease, cell, organ or tissue transplantation, comprising culturing peripheral blood mononuclear cells collected from a human in the presence of Notch ligand, GM-CSF and TGF-J3. And a method for preparing Langerhans cells for treating an autoimmune disease or an allergic disease.
- Various diseases can be treated as described above using the therapeutic Langerhans cells obtained by this method.
- As the cell a cell of the patient or a cell other than the patient is appropriately selected and used depending on the purpose of treatment.
- the present invention further provides the use of the above-mentioned Langerhans cells for suppressing infectious diseases such as cancer or AIDS, suppressing transplant rejection associated with cell, organ or tissue transplantation, treating graft-versus-host disease, treating autoimmune diseases or Provided is a method for treating an allergic disease or the like.
- the present invention further provides Langerhans cells for treating infectious diseases such as cancer or AIDS, suppressing transplant rejection associated with cell, organ or tissue transplantation, treating graft-versus-host disease, treating autoimmune diseases or allergic diseases, etc.
- infectious diseases such as cancer or AIDS
- suppressing transplant rejection associated with cell, organ or tissue transplantation treating graft-versus-host disease
- treating autoimmune diseases or allergic diseases etc.
- Sal lusto F, Lanzavecchia A Efficient presentation of soluble antigen by cultured human dendritic eel Is is maintained by granulocyte / macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor.J Exp Med 179: 1109-1118, 1994.
- Valladeau J Valladeau J, Ravel 0, Dezut ter-Dambuyant C, Moore K, Klei jmeer M, Liu Y, Duvert-Frances V, Vincent C, Schmi tt D, Davoust J, Caux C, LebecQue S, Saeland S: Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the format ion of Birbeck granules.Immunity 12: 71-81, 2000.
- the culture solutions and reagents used are as follows.
- the culture solution used was RPMI ⁇ 640 (Nissui Pharmaceutical, Tokyo) containing 2 ⁇ L L-glutamine, 50 U / m ⁇ penicillin, and 50 ⁇ g / ml streptomycin.
- Fetal calf serum (FCS) (Hyc lone, Logan, UT, USA) at 10%.
- GM-CSF was provided by Kirin Peel (Tokyo) and IL-4 was provided by Ono Pharmaceutical (Osaka).
- TGF- ⁇ and IL-15 were purchased from R & D Systems (Minneapolis, Thigh, USA).
- GM-CSF was used at 10 ng / ml
- IL-4 was used at 10 ng / mK
- TGF- / 3 was used at 10 ng / mK
- IL-15 was used at 10 ng / ml.
- Delta-1 was immobilized as follows.
- Delta-1 was immobilized on a culture plate by the method described previously (Ohishi K et al., Blood 98: 1402-1407, 2001; Oliishi K et al., Blood 95: 2847-2854, 2000; Oishi) K et al., J Clin Invest 110: 1165-1174, 2002).
- Delta-1 construct was purified from the supernatant of the transfected NS0 cell line.
- conditioned medium of NS0 cell line without genetic modification conditioned medium of NS0 cell line without genetic modification
- the antibodies used and sources are as follows.
- Monoclonal antibodies used FITC-anti-CDla antibody, PE-anti-HLA-ABC antibody (DAK0, Glostrup, Denmark); PE-anti-CD14 antibody, PE-anti-CD80 antibody, PE-anti-HLA-DR antibody (Becton Dickinson Immunocytometry, San Jose, CA, USA), PE-anti-Langerin (CD207) antibody, Anti-E-Cadherin antibody (ImmiHiotech, Marseille, France), PE-anti-CD86 antibody, (Becton Dickinson Pharm in gen, San Diego, CA, USA), FITC-anti-CCR6 antibody (R & D Systems) c HTC-picture se I G2a (Becton Dickinson), FITC-rat anti-mouse IgGl, PE reference se IgGl (Becton Dickinson Pharmingen), mouse IgG2b (Coulter Miami, FL, USA).
- the cells used in the present example were separated as follows.
- peripheral blood was collected from healthy Japanese with heparin.
- Peripheral blood mononuclear cells PBMCs
- PBMCs Peripheral blood mononuclear cells
- CD14-positive cells were separated from PBMCs using MACS Microbeads (Miltenyi Biotec, Auburn, CA, USA) (Mitani H et al., Br J Haematol 109: 288-295, 2000; Araki H et al., Br J Haematol 114: 681- 689, 2001).
- the purity of CD14-positive cells obtained by this method is more than 95%.
- non-specific esterase staining Moto Chemical, Tokyo
- CD14-positive cells were non-specific esterase positive.
- the obtained CD14-positive cells were cultured by the following method.
- CD14-positive cells were cultured at a concentration of 5 ⁇ 10 5 cells / ml on a 24-well tissue culture plate using RPMI 1640 supplemented with 10% FCS. Culture medium was changed every 3-4 days. After culturing under these conditions for 6 days, morphological observation was performed using a phase contrast microscope, and the number of viable cells was calculated by the trypan blue dye exclusion method.
- E-cadherin and Langerin For double staining of E-cadherin and Langerin, first react with anti-E-cadherin antibody, wash, add FITC-rat anti-mouse IgGl antibody, block with a sufficient amount of mouse IgGl, and Stained with Langerin antibody.
- GM-CSF + IL-4 + TGF- ⁇ (Ge issmann F et al .; ⁇ Exp Med 187: 961-966, 1998), which has been reported to support monocyte-to-LC differentiation in culture plates GM-CSF + IL-15 (Mohamadzadeii M et al., J Exp Med 194: 1013-1020, 2001), or GM-CSF + TGF- / 3 (Guironnet G et al., J Leukoc Biol 71: 845-853, 2002) The cells were cultured for 6 days in the presence of E.
- CD14-positive cells were cultured in a 24-well plate at a concentration of 5 ⁇ 10 5 solid Ail in the presence or absence of Delta-1 with the addition of GM-CSF + IL-4 + TGF-jS. After 6 days of culture, the cells were collected and stained with a monoclonal antibody against the antigen molecule shown in the figure.
- FIG. 1 shows the results of analysis of the traits of cells induced from CD14-positive cells by GM-CSF + IL-4 + TGF-j8 in the presence or absence of Delta-1.
- FIG. 1 Cells induced by GM-CSF + IL-4 + TGF-0 were morphologically DC-like, CDla-positive, CD14-negative, and expressed E-forcedherin, but did not express Langerin . Addition of Delta-1 did not change morphologically, but slightly increased E-cadherin expression (Fig. 1).
- FIG. 1 the outline shows the results of analysis using the control antibody, and the solid part shows the results of analysis using the monoclonal antibody used. Results are from a representative one of several experiments.
- CD14-positive cells were cultured in a 24-well plate at a concentration of 5 ⁇ 10 5 cells / ml with the addition of Delta-1 + GM-CSF + TGF- / 3. After 6 days of culture, cells were collected and stained with anti-CDla antibody and anti-Langerin antibody or anti-E-cadherin antibody, anti-Langerin antibody and anti-E-forcedherin antibody or anti-CCR6 antibody, and the analysis results were shown as dot plots.
- X 10 5 cells / ml at a concentration Delta- 1 + GM-CSF + TGF- / 3 was added to the culture.
- the cells were collected, stained with an anti-Langerin antibody and a monoclonal antibody against the antigen molecule shown in the figure, and the expression of each antigen molecule in the Langerin-positive cells was analyzed.
- Fig. 5 shows the results.
- the outline shows the analysis results with the control antibody, and the solid coating shows the analysis results with the monoclonal antibody used. Results are from a representative one of several experiments.
- the cells of the Langerin-positive fraction are class I and class II molecules of HLA-AB (; HLA-DR and co-stimulatory molecules) molecules) CD80 and CD86.
- DCs are present in the epidermis and dermis in the skin, and are called LC and dermal DC, respectively (Steinman Thigh et al., Annu Rev Immunol 9: 271-296, 1991; Banchereau J et al., Annu Rev I awake imol 18) : 767-811, 2000).
- DC has long been understood to be a monocyte / macrophage cell, but in the mouse bone marrow cell culture system, DCs form within colonies consisting of granulocytes and macrophages formed in the presence of GM-CSF. The presence of DC confirmed that DC was a cell belonging to the monocyte / macrophage system (Inaba K et al., Exp Med 176: 1693-1702, 1992).
- in vitro culture systems enabled the induction of LC from CD34-positive cells such as human umbilical cord blood or peripheral blood, and the induction of dermal DC from peripheral blood CD14-positive cells.
- CD34-positive cells such as human umbilical cord blood or peripheral blood
- dermal DC from peripheral blood CD14-positive cells.
- the cellular biology of the system DC has advanced dramatically and its understanding has been deepened (Caux C et al., Nature 360: 258-261, 1992; Caux C et al., J Exp Med 184: 695-706, 1996; Strunk D et al., Blood 87: 1292-1302, 1996; Geissmann F et al .; Exp Med 187: 961-966, 1998; Mohamadzade M et al., J Exp Med 194: 1013-1020, 2001; Guironnet G et al., J Leukoc Biol 71: 845-853, 2002) Based on the observation of the culture system over time, LC
- LC is present in the epidermis together with keratinocytes, and keratinocytes express Delta-1, which affects the differentiation of CD14-positive monocytes and dermal DC (OhisM K et al., Blood 98 : 1402-1407, 2001; Ohishi K. et al., Blood 95: 2847-2854, 2000; Lowell S et al., Curr Biol 10: 491-500, 2000), from the previously reported CD14 positive monocytes. The effect of Del-l on the culture system for inducing LC was examined.
- E-cadherin When CD14-positive monocytes are cultured in the presence of GM-CSF + IL-4 + TGF-jS or GM-CSF + IL-4 + TGF- / 3 + Delta-1, E-cadherin is obtained. Was expressed, but no expression of Langerin was observed. Langerin, a C-type lectin (1 ec t in), is a molecule closely related to birbeck granules and has high specificity for LC (Valladeau J et al., Imnumity 12: 71-81, 2000), it is difficult to say that cells in which this molecule is not expressed sufficiently retain the properties of LC.
- Keratinocytes not only express Delta-1 (Lowell S et al., Curr Biol 10: 491-500, 2000), but also secrete GM-CSF and TGF-; 3 (Luger TA et al., J Dermatol Sci. 13: 5-10, 1996).
- the culture system in which we induced LC from CD14-positive monocytes in vitro seems to be similar to the skin environment in vivo, and even in vivo, peripheral blood CD14-positive monocytes enter the epidermis through the dermis. It can be assumed that keratinocytes secrete or express GM-CSF, TGF-i8, and Delta-1 and differentiate into LC.
- Example 2 The reagents and antibodies used in Example 2 were as follows.
- CD40 ligand was purchased from Bender MedSystems (Vienna, Austria). TNF-a was provided by Dainippon Pharmaceuticals (Suita), and IL-2 was provided by Takeda Pharmaceutical (Osaka). The CD40 ligand was used at 1 g / ml, TNF- ⁇ at 20 ng / mK IL-2 at 20 IU / ml.
- the monoclonal antibodies used were PE-anti-CD40 antibody, PE-anti-CD83 antibody (Immimotech, Marseille, France) PE-anti-CD54 antibody (Beeton Dickinson Imm leak cytometry, San Jose, CA, USA).
- Real-tiie RT-PCR Real-time reversed transcriptase-polymerase chain reaction
- GAPDH endogenous gene
- forward primer 5 'GAA GGT GAA GGT CGG AGT 3'
- GAPDH reverse primer 5, GAA GAT GGT GAT GGG ATT TC 3, (SEQ ID NO: 5);
- GAPDH probe 5, (FAM)-TTG CCA TCA ATG ACC CCT TCA TTG AC- (TAMRA) 3 '(SEQ ID NO: 6).
- Amplification was performed using ABI Prism 7, 700 Seauence Detector (Applied Biosystems, Foster City, CA, USA).
- CD14-positive cells were cultured in the presence of Delta-1, GM-CSF, and TGF- ⁇ for 6 days, fixed with 2.5% daltaraldehyde, dehydrated with ethanol, and embedded in ebon. After staining the sections with lead citrate and peranil acetate, the cells were observed with a JEM-1200EX electron microscope (JE0L, Tokyo).
- the phagocytic ability of the induced LC was measured by the following method. Delta- 1, GM- CSF, TGF- 3 in the presence of 4 days, further floating CD40 ligand and TNF- flight to a 2 X 10 5 cells of the LC obtained by culturing for 2 days in addition to 10 FCS RPMI 1640 And 1 mg / ml ⁇ -dextran (min (Sigma, St. Louis, MO, USA) for 1 hour on ice or at 37 ° C. The FITC-dextran uptake reaction was interrupted with cold 1% FCS PBS, after which the cells were washed four times with 1 FCS PBS. FITC-dextran incorporation was measured on a FACS Calibur.
- the ELISPOT (enzymed-linked immunosorbent spot) method was performed with a slight modification of the previously reported method (Ikuta Y et al., Blood 99: 3717-3724, 2002).
- Mature LC was prepared by culturing CD14-positive cells in the presence of Delta-1, GM-CSF, and TGF-jS for 6 days, and adding CD40 ligand and TNF- ⁇ for the latter two days.
- the plate After washing the plate with PBS, the plate was treated with 10% AB type serum for 2 hours at 37 ° C to block nonspecific reactions. It modified 10 5 CD8-positive cells obtained healthy persons or these HLA-A0201-positive Mel an - A 26 _ 35 peptide (A27L) (ELAGIGILTV SEQ ID NO: 7) and pulse, is irradiated with (46 Gy) 4 ⁇ 10 4 mature LCs were cultured in RPMI 1640 with 10% AB serum in 24-well plates. On day 4 and day 7 of culture, IL-2 (20 ⁇ l / ml) was added. These CD8-positive cells were collected on day 10 of culture and used as effector cells.
- Modified Melan_A 26 - 35 peptide nothing or were pulse the (A27L) not pulsed T2 cells as the target cell.
- 1 ⁇ 10 4 effector cells and 5 ⁇ 10 4 target cells were co-cultured on ELISPOT plates. After 18 hours, the plate is washed with PBS containing 0.05% Tween, and then reacted with 1 g / ml of a biotinylated anti-interferon- ⁇ antibody (7-B6-1; MaMech) for 2.5 hours at 37 ° C and washed. Thereafter, the mixture was further reacted with 1 g / inl of streptavidin alkaline phosphatase (MaMech) for 1.5 hours.
- MoMech streptavidin alkaline phosphatase
- CD4-positive cells were stained with an alkaline phosphatase-linked substrate kit (BioRad, Hercules, CA, USA) and the number of spots was counted under a microscope.
- Stimulation of CD4-positive cells by mature LC was performed by the following method. 1 10 5 mature LC and 2 X 10 5 autologous CD4-positive cells were stained with anti-CD3 antibody; culture (UCHT1, 0.5 mg / ml BD P arMingen, SanDiego, CA, USA) in 24 ⁇ El plates in the presence of Then, on the fourth day of the culture, IL-2 (20 l / ml) was added, and on the seventh day of the culture, the number of CD4-positive cells was calculated. Instead of mature LC, The same was performed using mature DCs induced from GM-CSF, IL-4 and CD40 ligand, TNF- ⁇ ; from CD14-positive monocytes.
- the HES-1 gene is known as a target gene for a notch signal (Schroeter EH et al., Nature 393: 382-386, 1998; Struhl G et al., Cell 93: 649-660, 1998). Therefore, in order to confirm whether Delta-1 transmits a Notch signal to LC, the effect of Delta-1 on HES-1 gene expression was examined (FIG. 6). When Delta-1 was present in the culture system, HES-1 expression was increased about 8-fold compared to when Delta-1 was not present. It was confirmed that De11a-1 acts on CD14 positive cells. FIG. 6 shows the enhancement of HES-1 gene expression by Delta-1 in CD14-positive cells. The expression of the HES-1 gene in the presence and absence of Delta-1 was examined. The results were expressed as a ratio of the expression of the HES-1 gene to the expression of the GAPDH gene. A representative example of two experiments is shown.
- the cells had many elongated cell processes, and also contained Birbeck granules in the cytoplasm (Fig. 7).
- Figure 7 shows an electron microscope image of the cultured cells.
- the original magnification of the left panel is 8,000x and the bar is 2111, and the original magnification of the right panel is 30,000x and the bar is 0.5. m.
- LC phagocytic activity of LC prepared from Delta-1, GM-CSF, and TGF-] 8 from CD14-positive cells was examined by FITC-dextran uptake (FIG. 8). LC has incorporated FITC-dextran. The IX produced was found to be phagocytic.
- FIG. 8 shows the results of an examination of the uptake of FITC-dextran by LC.
- LCs derived from CD14-positive cells generated by Delta-1, GM-CSF and TGF-j8 were reacted with FITC-dextran at 37 ° C or on ice for 1 hour. After washing three times, analysis was performed using a FACS Calibur. Similar The results were obtained in three experiments.
- FIG. 9 shows the expression of HLA-ABC, HLA-DR, CD80, CD86, C, CD54, and CD83 in LC matured with CD40 ligand and TNF- ⁇ .
- CD14-positive cells were cultured with Delta-1, GM-CSF, and TGF-i3.
- CD4 ligand and TNF- ⁇ were additionally added on the fourth day of the culture, and the cells were collected on the sixth day.
- mature LCs generated from CD14-positive cells activate peptide-specific CD8-positive cells.
- Mature LCs were prepared from CD14-positive cells derived from HLA-A0201-positive healthy persons using Delta-1, GM-CSF, TGF-j8, CD40 ligand, and TNF- ⁇ . 2 ⁇ 10 5 autologous CD8 + T cells were transformed into 4 ⁇ 10 4 modified Melan-A 26 — 35 peptides (A27L) Saturated mature LCs were stimulated for 10 days.
- CD8-positive cells were harvested and co-cultured 1 X number of CD8 positive cells and the modified Melan-A 26 _ 35 peptide (A27L) (ELAGIGILTV) 5 x 10 4 cells of the T2 cells pulsed with the ELISPOT plate. Eighteen hours later, the number of autologous CD8-positive T cells that produce inferon ferrona was calculated. Each bar represents the average of two measurements. Two experimental examples are shown.
- FIG. 11 shows the results of stimulation of autologous CD4-positive cells by mature LC and mature DC.
- mature IX using Delta-1, GM-CSF, TGF- ⁇ , CD40 ligand, TNF-H, and GM-CSF, IL-4, CD40 ligand, TNF- ⁇
- IL-2 was added on day 4 of culture.
- IL-2 was added on day 7 of culture.
- the number of CD4-positive T cells was calculated. Each bar represents the average of four measurements. A representative example of the two experiments is shown.
- IL-4 and CD40 ligand, and higher than mature dendritic cells (DC) induced by TNF-H.
- DC dendritic cells
- Langerhans cells By culturing human peripheral blood mononuclear cells in the presence of Notch ligand, GM-CSF and TGF-) 3, Langerhans cells, which had not been achieved conventionally, can be prepared.
- the Langerhans cells can be obtained in the form of immature cells or mature cells.
- vaccine cell therapy ⁇ , infectious diseases, suppression of graft rejection associated with cell, organ or tissue transplantation, treatment of graft-versus-host disease It can be used for the treatment of autoimmune diseases or allergic diseases.
- the Langerhans cells obtained by the method of the present invention can be used for cytobiological studies on Langerhans cells.
- Langerhans cells prepared by the method of the present invention can be used for vaccine cell therapy, that is, suppression of transplant rejection associated with cancer, infectious disease, cell, organ, or tissue transplantation, and prevention of graft-versus-host disease. It can be used for treatment, self-immune disease or allergic disease. All publications cited herein are incorporated by reference in their entirety. It will be readily apparent to those skilled in the art that various modifications and alterations of the present invention are possible without departing from the technical concept and the scope of the invention described in the appended claims. The present invention is intended to cover such modifications and variations.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005511953A JPWO2005007839A1 (ja) | 2003-07-22 | 2004-07-22 | ノッチリガンドDelta−1、GM−CSF、TGF−βを用いたヒト末梢血単核球であるCD14陽性細胞からのランゲルハンス細胞の調製方法 |
EP04748047A EP1688483A4 (en) | 2003-07-22 | 2004-07-22 | METHOD FOR PRODUCING A LANGERHANSSCHEN CELL FROM A CD14 POSITIVE CELL WHICH IS A HUMAN MONONUCLEAR PERIPHERAL BLOOD CELL USING THE NOTCH LIGAND DELTA-1, GM-CSF AND TGF-BETA |
AU2004258032A AU2004258032A1 (en) | 2003-07-22 | 2004-07-22 | Method of preparing langerhans cell from CD14-positive cell being human peripheral-blood mononuclear cell with use of notch ligand delta-1, GM-CSF and TGF-beta |
US10/565,273 US20060182721A1 (en) | 2003-07-22 | 2004-07-22 | Method of preparing langerhans cell from cd14-positive cell being human peripheral blood mononuclear cell with use of notch ligand delta-1, gm-csf and tgf-ss |
CA002533121A CA2533121A1 (en) | 2003-07-22 | 2004-07-22 | Method of preparing langerhans cell from cd14-positive cell being human peripheral-blood mononuclear cell with use of notch ligand delta-1, gm-csf and tgf-.beta. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-277892 | 2003-07-22 | ||
JP2003277892 | 2003-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005007839A1 true WO2005007839A1 (ja) | 2005-01-27 |
Family
ID=34074672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/010783 WO2005007839A1 (ja) | 2003-07-22 | 2004-07-22 | ノッチリガンドDelta-1、GM-CSF、TGF-βを用いたヒト末梢血単核球であるCD14陽性細胞からのランゲルハンス細胞の調製方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060182721A1 (ja) |
EP (1) | EP1688483A4 (ja) |
JP (1) | JPWO2005007839A1 (ja) |
AU (1) | AU2004258032A1 (ja) |
CA (1) | CA2533121A1 (ja) |
WO (1) | WO2005007839A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006054415A1 (ja) * | 2004-11-19 | 2008-05-29 | 祥 松下 | 免疫応答修飾活性の試験管内評価方法 |
JP2008546413A (ja) * | 2005-06-23 | 2008-12-25 | マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー | 心筋細胞集団 |
WO2013005649A1 (ja) * | 2011-07-01 | 2013-01-10 | 協和発酵キリン株式会社 | 抗ヒトccr6抗体 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2905380B1 (fr) * | 2006-09-04 | 2008-12-05 | Engelhard Lyon Sa | Procede de production de cellules de langerhans et/ou de cellules de dentritiques interstitielles/dermiques a partir de monocytes cd14+ |
FR3132146A1 (fr) * | 2022-01-27 | 2023-07-28 | Genoskin | Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002509717A (ja) * | 1998-03-30 | 2002-04-02 | イ・デ・エム・イミュノ−デジネ・モレキュル | 抑制された単球由来細胞、それらの調製法及びそれらの医薬組成物における使用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633929B1 (en) * | 1992-04-01 | 2004-03-03 | The Rockefeller University | METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS |
EP0974357A1 (en) * | 1998-07-16 | 2000-01-26 | Schering-Plough | Chemokines as adjuvants of immune response |
US20040022761A1 (en) * | 2001-05-11 | 2004-02-05 | Banchereau Jacques F | Compositions and methods for producing antigen-presenting cells |
FR2833271B1 (fr) * | 2001-12-10 | 2004-09-17 | Coletica | Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles |
-
2004
- 2004-07-22 CA CA002533121A patent/CA2533121A1/en not_active Abandoned
- 2004-07-22 JP JP2005511953A patent/JPWO2005007839A1/ja not_active Abandoned
- 2004-07-22 WO PCT/JP2004/010783 patent/WO2005007839A1/ja active Application Filing
- 2004-07-22 US US10/565,273 patent/US20060182721A1/en not_active Abandoned
- 2004-07-22 EP EP04748047A patent/EP1688483A4/en not_active Withdrawn
- 2004-07-22 AU AU2004258032A patent/AU2004258032A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002509717A (ja) * | 1998-03-30 | 2002-04-02 | イ・デ・エム・イミュノ−デジネ・モレキュル | 抑制された単球由来細胞、それらの調製法及びそれらの医薬組成物における使用 |
Non-Patent Citations (3)
Title |
---|
ARRIGHI J.-F. ET AL: "TNF-alpha induces the generation of Langerin/(CD207)+ immature Langerhans-type dendritic cells from both CD14-CD1a- and CD14+CD1a- precursors derived from CD34+ cord blood cells", EUR. J. IMMUNOL., vol. 33, no. 7, July 2003 (2003-07-01), pages 2053 - 2063, XP002981321 * |
See also references of EP1688483A4 * |
TSIATAS M.L. ET AL: "A Novel Culture Environment for Generating Mature Human Dentritic Cells from Peripheral Blood CD14+ Cells", ANTICANCER RES., vol. 21, no. 2A, 2001, pages 1199 - 1206, XP002981322 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006054415A1 (ja) * | 2004-11-19 | 2008-05-29 | 祥 松下 | 免疫応答修飾活性の試験管内評価方法 |
JP4886521B2 (ja) * | 2004-11-19 | 2012-02-29 | 祥 松下 | 免疫応答修飾活性の試験管内評価方法 |
JP2008546413A (ja) * | 2005-06-23 | 2008-12-25 | マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー | 心筋細胞集団 |
WO2013005649A1 (ja) * | 2011-07-01 | 2013-01-10 | 協和発酵キリン株式会社 | 抗ヒトccr6抗体 |
Also Published As
Publication number | Publication date |
---|---|
EP1688483A1 (en) | 2006-08-09 |
CA2533121A1 (en) | 2005-01-27 |
EP1688483A4 (en) | 2007-09-12 |
JPWO2005007839A1 (ja) | 2006-08-31 |
US20060182721A1 (en) | 2006-08-17 |
AU2004258032A1 (en) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2577125C (en) | Mature dendritic cell compositions and methods for culturing same | |
EP2058389B1 (en) | Defined dendritic cell maturation medium comprising TNF-alpha, IL-1beta, IL-6 | |
JP2023058687A (ja) | ガンマデルタt細胞の増幅、組成物およびその使用 | |
US7198948B2 (en) | Methods and compositions for obtaining mature dendritic cells | |
US9944899B2 (en) | Tolerogenic dendritic cells, method for their production and uses therof | |
US20030134415A1 (en) | Th1 cell adoptive immunotherapy | |
US20030124091A1 (en) | Endothelial cell derived hematopoietic growth factor | |
Zhang et al. | Development of dendritic cells in vitro from murine fetal liver–derived lineage phenotype-negative c-kit+ hematopoietic progenitor cells | |
Kalady et al. | Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity | |
KR101518972B1 (ko) | 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도 | |
US20030134341A1 (en) | Th1 cell adoptive immunotherapy | |
US20040022761A1 (en) | Compositions and methods for producing antigen-presenting cells | |
WO2005007839A1 (ja) | ノッチリガンドDelta-1、GM-CSF、TGF-βを用いたヒト末梢血単核球であるCD14陽性細胞からのランゲルハンス細胞の調製方法 | |
Alldawi et al. | Effect of prostaglandin E2, lipopolysaccharide, IFN-γ and cytokines on the generation and function of fast-DC | |
Xiao et al. | TGF-β1 synergizes with GM-CSF to promote the generation of glial cell-derived dendriform cells in vitro | |
WO1998023728A1 (en) | Cellular adjuvant | |
WO2022097664A1 (ja) | 血小板溶解物を用いた樹状細胞の調製法 | |
AU718873B2 (en) | Cellular adjuvant | |
EP2669367A1 (en) | A human dendritic cell line | |
Shklovskaya et al. | Balancing Tolerance and Immunity | |
JP2000504230A (ja) | 殺腫瘍性tリンパ球の製造法 | |
JP2001026545A (ja) | 免疫応答活性化製剤 | |
FR2789089A1 (fr) | Lymphocytes t humains effecteurs exprimant la molecule cd86 et possedant des proprietes immunodulatrices, costimulatrices et cytotoxiques, leurs procedes d'obtention et leurs applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511953 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2533121 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006182721 Country of ref document: US Ref document number: 10565273 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004258032 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004748047 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004258032 Country of ref document: AU Date of ref document: 20040722 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004258032 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004748047 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10565273 Country of ref document: US |